Form D · Biotechnology
RAPT Therapeutics, Inc.
South San Francisco, CA · CIK 0001673772
Offering snapshot reported Jan 3, 2025 · SEC filing
- Reported sold
- $150M Offering amount: $150M
- Investors reported
- 20 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 27, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 3, 2025 | Initial | $149,984,200 | No comparison | 20 | SEC filing |
| Jun 3, 2022 | Initial | $50,000,000 | No comparison | 1 | SEC filing |
| Jun 20, 2019 | Amendment | $37,103,785 | $14,468,987vs Jan 2, 2019 | 24 | SEC filing |
| Jan 2, 2019 | Initial | $22,634,798 | No comparison | 12 | SEC filing |
| Jan 4, 2018 | Initial | $29,927,851 | No comparison | 10 | SEC filing |
| May 5, 2016 | Initial | $50,000,000 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $6.5M
- Finders' fees
- $0
- Form D file number
- 021-534152
The Total Offering Amount and Total Amount Sold includes the exercise price of $0.0001 per share, payable on the exercise of the warrants by the investors.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Leerink Partners LLC | 39011 |
Source: Form D, filed Jan 3, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Dirk Brockstedt | Executive |
| Michael Giordano | Director |
| David V. Goeddel | Director |
| Mary Ann V. Gray | Director |
| Eric Hall | Executive |
| Rekha Hemrajani | Executive |
| William Ho | Executive |
| Paul Kassner | Executive |
| Linda Kozick | Director |
| Tim Lin | Executive |
| Lori Lyons Williams | Director |
| William J. Rieflin | Director |
| Wendye Robbins | Director |
| Beth Seidenberg | Director |
| Brian Wong | Director, Executive |
| David Wustrow | Executive |
| Rodney Young | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
561 Eccles Avenue
South San Francisco, CA, 94080
South San Francisco, CA, 94080